Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Autor: Kaj Blennow, Sylvain Lehmann, Nicholas J. Ashton, Jordi Pegueroles, Rafael Blesa, Maria Florencia Iulita, Alberto Lleó, Miren Altuna, Valle Camacho, Henrik Zetterberg, Maria Carmona-Iragui, Daniel Alcolea, Diana Garzón, Susana Fernández, Juan Lantero-Rodriguez, Santiago Medrano-Martorell, Juan Fortea, Jordi Clarimón, Thomas K. Karikari, Olivia Belbin, Alexandre Bejanin, Laura Videla, Sílvia Valldeneu, Bessy Benejam, Isabel Barroeta, Victor Montal
Přispěvatelé: Hospital de la Santa Creu i Sant Pau, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC), Universitat Autònoma de Barcelona (UAB), Sahlgrenska Academy at University of Gothenburg [Göteborg], Sahlgrenska University Hospital [Gothenburg], UK Dementia Research Institute (UK DRI), University College of London [London] (UCL), Institute of Neurology [London], Fundació Catalana de Síndrome de Down [Barcelona], University of Gothenburg (GU), King‘s College London, IMIM-Hospital del Mar, Generalitat de Catalunya, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Neurosciences de Montpellier (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Herrada, Anthony
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
General Physics and Astronomy
MESH: Cognition
Disease
Gastroenterology
Cognition
0302 clinical medicine
Neurofilament Proteins
Medicine
Phosphorylation
MESH: Neurofilament Proteins
Cerebral Cortex
education.field_of_study
MESH: Middle Aged
Multidisciplinary
Area under the curve
Middle Aged
Alzheimer's disease
MESH: Amyloid beta-Peptides
MESH: tau Proteins
Area Under Curve
Disease Progression
Biomarker (medicine)
MESH: Disease Progression
Female
medicine.symptom
Adult
medicine.medical_specialty
Down syndrome
Science
Population
tau Proteins
MESH: Atrophy
Predictive markers
Asymptomatic
Article
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
MESH: Cross-Sectional Studies
Atrophy
Alzheimer Disease
Internal medicine
Humans
Dementia
education
MESH: Humans
Amyloid beta-Peptides
MESH: Phosphorylation
business.industry
[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
MESH: Adult
MESH: Down Syndrome
General Chemistry
medicine.disease
MESH: Cerebral Cortex
MESH: Male
Cross-Sectional Studies
030104 developmental biology
MESH: Biomarkers
MESH: Area Under Curve
Down Syndrome
business
MESH: Female
MESH: Alzheimer Disease
Biomarkers
030217 neurology & neurosurgery
Zdroj: Nature Communications
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.4304. ⟨10.1038/s41467-021-24319-x⟩
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
ISSN: 2041-1723
DOI: 10.1038/s41467-021-24319-x
Popis: Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults.
Databáze: OpenAIRE
Externí odkaz: